Home
News
Create
Screeners
Insights
Prism Medico & Pharmacy
31.
99
+0.93
(+2.99%)
Market Cap
₹19.36 Cr
PE Ratio
31.37
Industry
Financial Services
Buy
Sell
Company Performance:
1D
+2.99%
1M
+22.85%
6M
+52.48%
1Y
+104.15%
5Y
+254.66%
View Company Insights
Latest news about Prism Medico & Pharmacy
Prism Medico and Pharmacy Limited Submits Q4FY26 Compliance Certificate to Stock Exchanges
8 days ago
Prism Medico and Pharmacy Limited submitted its Q4FY26 confirmation certificate under SEBI Regulation 74(5) to BSE and MSEI for the quarter ended March 31, 2026. The certificate, issued by RTA Purva Sharegistry (India) Pvt. Ltd., confirms regulatory compliance with no share dematerialization activity recorded during the quarter.
Prism Medico and Pharmacy Limited Reports No Promoter Share Encumbrance in FY26
Apr 08, 2026
Prism Medico and Pharmacy Limited Confirms No Non-Convertible Securities Issued for Q4FY26
Apr 08, 2026
Prism Medico Files Regulatory Compliance for Non-Convertible Securities Q4 FY26
Apr 07, 2026
Prism Medico and Pharmacy Limited Clarifies Stock Price Movement Under SEBI Regulation 30
Mar 31, 2026
More news about Prism Medico & Pharmacy
25
Mar 26
Prism Medico Submits Scrutinizer's Report with 99.98% EGM Approval Results
Prism Medico and Pharmacy Limited has submitted the scrutinizer's report for its March 20, 2026 EGM, revealing 99.98% shareholder approval for both special business resolutions. The company received overwhelming support from 43 voters casting 3,76,133 votes for the alteration of Articles of Association and preferential issue of equity shares and convertible warrants, enabling the company to proceed with its ₹25.00 crore fundraising plan for pharmaceutical manufacturing expansion and infrastructure development.
23
Feb 26
Prism Medico and Pharmacy Board Approves Rs. 25 Crore Equity Fundraising Through Preferential Issue
Prism Medico and Pharmacy Limited's board approved a Rs. 25 crore fundraising through preferential allotment of 75 lakh equity shares and 50 lakh convertible warrants at Rs. 20 each on February 23, 2026. The board also amended Articles of Association to facilitate future securities issuance and scheduled an EGM for March 20, 2026, for shareholder approval. The allocation covers both promoter and non-promoter categories with detailed investor-wise distribution already finalized.
13
Feb 26
Prism Medico Reports Q3FY26 Loss of ₹1.34 Lakhs, Revenue Drops to ₹7.10 Lakhs
Prism Medico and Pharmacy Limited announced Q3FY26 financial results showing net loss of ₹1.34 lakhs compared to ₹0.96 lakhs loss in Q3FY25, with revenue declining significantly to ₹7.10 lakhs from ₹20.86 lakhs year-on-year. However, the company's year-to-date performance demonstrates profitability with net profit of ₹55.91 lakhs on total income of ₹218.60 lakhs for the nine-month period.
14
Jan 26
Prism Medico and Pharmacy Limited Submits SEBI Depositories Compliance Certificate for Q3FY26
Prism Medico and Pharmacy Limited submitted its Q3FY26 confirmation certificate under SEBI Depositories Regulations for the quarter ended December 31, 2025. The filing, made on January 14, 2026, through RTA Purva Sharegistry, confirms no dematerialisation activity occurred during the quarter. The company maintains compliance with regulatory requirements across BSE and MSEI exchanges.
21
Nov 25
Prism Medico Reports Q2 Loss Amid Revenue Decline, Corrects Financial Statement Filing
Prism Medico & Pharmacy reported a net loss of ₹0.10 crore for Q2 ended September 30, with revenue declining 68.75% to ₹0.50 crore. Despite the quarterly loss, the company posted a half-year profit of ₹57.25 lakh. The operating profit margin fell to -20.00% from 40.88% in the previous quarter. The company also re-uploaded its complete financial statements to stock exchanges, addressing an initial filing error.
12
Sept 25
Prism Medico & Pharmacy Limited Reports Remarkable Q1 Performance with ₹65.73 Lakh Net Profit
Prism Medico & Pharmacy Limited announced a significant financial turnaround in Q1. Revenue from operations increased to ₹158.87 lakhs from ₹7.28 lakhs in the previous quarter. Net profit reached ₹65.73 lakhs, compared to ₹4.15 lakhs in Q4 and a loss of ₹9.00 lakhs year-over-year. The company demonstrated improved operational efficiency and cost management despite the revenue surge. The Board of Directors approved these unaudited standalone financial results, which were reviewed by auditors and submitted to stock exchanges in compliance with SEBI regulations.
Prism Medico & Pharmacy
31.
99
+
0.
93
(+
2.
99
%)
1 Year Returns:
+104.15%
Industry Peers
Bajaj Finance
934.75
(-
0.
44
%)
Shriram Finance
1,044.55
(-
0.
07
%)
Jio Financial Services
238.51
(+
1.
60
%)
Muthoot Finance
3,586.90
(-
0.
65
%)
Cholamandalam Investment
1,565.60
(-
1.
49
%)
SBI Cards
686.20
(+
0.
95
%)
Sundaram Finance
4,902.10
(-
1.
46
%)
M&M Financial Services
300.25
(-
1.
99
%)
Authum Inv & Infr
484.80
(+
3.
00
%)
Poonawalla Fincorp
424.10
(+
0.
38
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO